Clinical Development Contract Manufacturing Manufacturing Pharmacy 
Pharmaceutical Technology
JUNE 6, 2023
The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. PF-06835375 Overview PF-06835375 is under development for the treatment of seropositive systemic lupus erythematosus, primary immune thrombocytopenia (ITP) and rheumatoid arthritis.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. Pfizer overview Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. Pfizer overview Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). Pfizer overview Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals.
The Pharma Data
NOVEMBER 5, 2020
Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Updates from the clinical pipeline include: Dupixent ® (dupilumab). Corporate and Business Development Update. Business Highlights.
Expert insights. Personalized for you.
100 
Let's personalize your content